Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PTAFR | P25105 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138427 | 0.92 | KCNH2 (0.46) | SETD7KCNH2HRH1POLBMAPT | |
| SCHEMBL3138558 | 0.89 | ALDH1A1 (0.46) | SETD7KCNH2POLBMAPTTHRB | |
| SCHEMBL3132968 | 0.88 | KCNH2 (0.43) | SETD7KCNH2HRH1POLBTHRB | |
| SCHEMBL3132978 | 0.88 | KCNH2 (0.43) | SETD7KCNH2HRH1POLBTHRB | |
| SCHEMBL3131124 | 0.84 | HRH1 (0.57) | SETD7KCNH2HRH1 | |
| SCHEMBL3139075 | 0.84 | HPGD (0.46) | SETD7KCNH2HRH1POLBMAPT | |
| SCHEMBL3147395 | 0.82 | NPC1 (0.48) | SETD7KCNH2PTAFRHTR2CMAPT | |
| Hydrochloric Acid SCHEMBL3139244 | 0.82 | KCNH2 (0.46) | SETD7KCNH2HRH1 | |
| Hydrochloric Acid SCHEMBL3137251 | 0.81 | SETD7 (0.51) | SETD7KCNH2DRD2HTR2CHRH1 | |
| SCHEMBL3131638 | 0.78 | SETD7 (0.51) | SETD7KCNH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2067777-B1 | OXEPIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-8222419-B2 | Oxepin derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20100004456-A1 | Oxepin derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2067777-A1 | OXEPIN DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004456-A1 | Oxepin derivative | HRH4, HRH3, HCRTR2 | SETD7 2087/4885KCNH2 1909/4885PTAFR 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.